STXS (Stereotaxis) Common Stock : $0.09 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Stereotaxis Common Stock?

Stereotaxis's quarterly common stock increased from Jun. 2024 ($0.08 Mil) to Sep. 2024 ($0.09 Mil) but then stayed the same from Sep. 2024 ($0.09 Mil) to Dec. 2024 ($0.09 Mil).

Stereotaxis's annual common stock increased from Dec. 2022 ($0.08 Mil) to Dec. 2023 ($0.08 Mil) and increased from Dec. 2023 ($0.08 Mil) to Dec. 2024 ($0.09 Mil).

Stereotaxis Common Stock Historical Data

The historical data trend for Stereotaxis's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stereotaxis Common Stock Chart

Stereotaxis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.07

0.08

0.09

Stereotaxis Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															0.08	0.08	0.08	0.09	0.09

Stereotaxis Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Stereotaxis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

RJR1:Germany

Address

710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101

Website

https://www.stereotaxis.com

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Executives

Paul J Isaac	10 percent owner	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer	director	5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry	officer: Chief Legal Officer & Secretar	4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin	director	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat	director	2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani	director	4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite	officer: VP Research & Development	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730